Clinical Trials Logo

Filter by:
NCT ID: NCT05590273 Terminated - Brain Cancer Clinical Trials

Forgotten Voices: Addressing Unmet Needs in Brain Tumor Caregivers

AIM 2
Start date: November 3, 2022
Phase: N/A
Study type: Interventional

To conduct a mixed-method Phase Ia Define Trial of caregivers' participation in CALM therapy with post-session surveys and individual exit interviews in order to evaluate suitability and adapt the CALM intervention to the needs of caregivers in neuro-oncology.

NCT ID: NCT05589038 Terminated - Healthy Clinical Trials

A Study of a Baby Wash/Shampoo and Baby Lotion Versus Baby Wash/Shampoo Alone for Impact on Skin Barrier and Microbiome on Newborns

Start date: October 25, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate the tolerance of a baby wash/shampoo alone and the tolerance of a regimen of a baby wash/shampoo and baby lotion in a newborn population.

NCT ID: NCT05585879 Terminated - Clinical trials for Colorectal Screening

Demonstrating Effective Salvage of Inadequate Colonoscopies

Start date: November 3, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to demonstrate that the use of the Pure-Vu EVS System can salvage inadequately prepared optical colonoscopies (OCs) to adequate OCs.

NCT ID: NCT05579977 Terminated - Obesity Clinical Trials

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

Start date: October 27, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Rybelsus. Those in the obesity part of the study, will receive either active study drug or placebo. The study will last for about 36 weeks except for the first 25% of the participants that enter in which case the study will last for approximately 48 weeks. during this time there will be visits every 4 weeks with phone calls in between.

NCT ID: NCT05579444 Terminated - Obesity Clinical Trials

Systems Biology of Gastrointestinal and Related Diseases

Start date: November 11, 2022
Phase:
Study type: Observational

This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and remissions, or progression of their disease.

NCT ID: NCT05567783 Terminated - Influenza A Clinical Trials

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Start date: October 30, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIR-2482 compared to placebo in preventing influenza A illness in healthy adults 18 to <65 years of age without pre-existing risk factors for serious complications from influenza infection.

NCT ID: NCT05563610 Terminated - Penicillin Allergy Clinical Trials

Oral Penicillin Challenge and Allergy De-labeling in Children

Start date: September 26, 2022
Phase: Phase 4
Study type: Interventional

The primary purpose of this study is to investigate the portion of penicillin allergy labels that are not true allergies using oral amoxicillin challenges among pediatric patients. The secondary purpose is to evaluate the safety and feasibility of administering oral penicillin allergy challenges in the Pediatric Emergency Department.

NCT ID: NCT05562011 Terminated - Clinical trials for Perioperative/Postoperative Complications

Feasibility of a New Ambulatory Multi-vital Signs Monitor

Start date: August 18, 2021
Phase: N/A
Study type: Interventional

The purpose of this research is evaluate vital signs (VS), which include non-invasive blood pressure, pulse rate, respiratory rate and Oxygen Saturation (SpO2) using a portable wrist monitoring device called a Caretaker. This device has been cleared by the Food and Drug Administration (FDA) for use and allows the study team to check vital signs in a participant's normal setting. Participation in this study will involve wearing this portable device at 2 different time points: 1. for up to 24 hours immediately during and after the participant's preoperative visit to obtain baseline vital signs during normal activity and during sleep and 2. after surgery up to 24 hours while participant recovers prior to discharge from the hospital

NCT ID: NCT05556265 Terminated - Alopecia Areata Clinical Trials

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Start date: November 8, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of Deucravacitinib versus placebo at Week 24 and safety and tolerability of Deucravacitinib versus placebo in adults with Alopecia Areata.

NCT ID: NCT05555173 Terminated - Chronic Pain Clinical Trials

IVs With Buzzy in Chronic Pain Patients

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

The investigators are conducting a study to compare the effectiveness of the Buzzy® device with that of no pain relief method for IV placement in adults with chronic pain receiving lidocaine infusions.